This page uses content from Wikipedia and is licensed under CC BY-SA.

Amibegron

Amibegron
Amibegron.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H26ClNO4
Molar mass403.898 g/mol g·mol−1
3D model (JSmol)
  (verify)

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.[1][2]

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]

References

  1. ^ Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, et al. (February 2008). "Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders". Neuropsychopharmacology. 33 (3): 574–87. doi:10.1038/sj.npp.1301424. PMID 17460614.
  2. ^ Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression". Pharmacology, Biochemistry, and Behavior. 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519.
  3. ^ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.